Extracellular Caspase-8 Dependent Apoptosis on Cancer Cells and Normal Cells by ICD-85 (Venom Derived Peptides)

Publish Year: 1391
نوع سند: مقاله کنفرانسی
زبان: English
View: 363

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

ICBCMED08_168

تاریخ نمایه سازی: 29 فروردین 1397

Abstract:

Our previous studies revealed an inhibitory effect of ICD-85 (venom derivedpeptides) on MDA-MB231 and HL-60 cell lines, through induction ofapoptosis. The purpose of this study was to investigate apoptosis-inducedmechanism on HeLa and MRC-5 cells by ICD-85 through activation of caspase-8.Cell viability, cytosolic enzyme Lactate Dehydrogenase (LDH) and cellmorphology were assessed under unexposed and ICD-85 exposedconditions.Caspase-8 activity was assayed by caspase-8 colorimetric assay Kit.The results show that Inhibitory Concentration 50% (IC50) value of ICD-85 forHeLa cells at 24 h was estimated and found to be 25.32±2.15μg/ml.Furthermore, treatment of HeLa cells with ICD-85 at concentrations of 1.6×10and 2.6 ~10μg/ml did not significantly increase LDH release. Morphologicalchanges in HeLa cells on treatment with ICD-85 compared with untreated HeLacells consistent with an apoptotic mechanism of cell death, such as cellshrinkage which finally results in the generation of apoptotic bodies. However,when MRC-5 cells were exposed to ICD-85, no significant changes in cellmorphology and LDH were observed at concentrations below 2.6 ~10μg/ml.Also, the apoptosis-induction mechanism by ICD-85 on HeLa cells was foundthrough activation of caspase-8 and the activity of caspase-8 in HeLa cells was1.5 folds more than its activity on MRC-5 cells. Therefore, the apoptosisinducedmechanisms by ICD-85 are through activation of caspase-8 andconcerning the least cytotoxic effect on MRC-5 cells,ICD-85 may be used asanticancer compound to inhibit growth of cancer cells.

Authors

Ali Sarzaeem

AryoGen Biopharma co, Tehran, Iran